Myeloproliferative Neoplasms and Ischemic Stroke

Abstract

Abstract:

【Abstract】 Myeloproliferative neoplasms (MPNs) often occur with vascular complications, most commonly involving cerebrovascular, and ischemic stroke is the most common. MPNs as a cause of ischemic stroke are different to other causes of stroke in diagnosis and treatment. And leukocytosis and JAK2V617F mutations have been found associated with ischemic stroke. In this paper, an updated overview of morbidity and pathogenesis, prevention and treatment in MPNs with ischemic stroke is presented.

Key words: Myeloproliferative neoplasms; Ischemic stroke; Thrombosis; JAK2V617F mutation

摘要：

【摘要】骨髓增殖性肿瘤常出现血管并发症，最常累及脑血管，以缺血性卒中最为常见。骨髓增殖性肿瘤作为缺血性卒中的病因之一，其诊断与治疗不同于其他病因所致卒中。白细胞增多、JAK2V617F基因突变等相继被发现与缺血性卒中相关。本文对骨髓增殖性肿瘤伴缺血性卒中的发生、机制及防治的新进展进行综述。

关键词: 骨髓增殖性肿瘤; 缺血性卒中; 血栓形成; JAK2V617F突变

BAI Bei-Bei, CHEN Ye.. Myeloproliferative Neoplasms and Ischemic Stroke[J]. Chinese Journal of Stroke, 2013, 8(07): 585-.

白贝贝，陈烨. 骨髓增殖性肿瘤与缺血性卒中[J]. 中国卒中杂志, 2013, 8(07): 585-.

References

1 Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia:rationale and important changes[J]. Blood, 2009, 114:937-951.

2 Landolfi R, Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms[J]. Haematologica, 2011, 96:183-186.

3 Colombi M, Radaelli F, Zocchi L, et al. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients[J]. Cancer, 1991, 67:2926-2930.

4 Jensen MK, de Nully Brown P, Nielsen OJ, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area[J]. Eur J Haematol, 2000, 65:132-139.

5 Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia:prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia[J]. Arch Intern Med, 2005, 165:2651-2658.

6 Reisner SA, Rinkevich D, Markiewicz W, et al. Cardiac involvement in patients with myeloproliferative disorders[J]. Am J Med, 1992, 93:498-504.

7 Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia:a study of the predictive factors in a series of 148 patients[J]. Leukemia, 1999, 13:150-154.

8 Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera:long-term results in 163 patients[J]. Haematologica, 2000, 85:1011-1018.

9 Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera[J]. J Clin Oncol, 2005, 23:2224-2232.

10 Pardanani A, Lasho TL, Hussein K, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm:assessment of value in a series of 664 consecutive patients[J]. Mayo Clin Proc, 2008, 83:457-459.

11 Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera[J]. Blood, 2007, 109:2446-2452.

12 De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia:incidence, risk factors, and effect of treatments[J]. Haematologica, 2008, 93:372-380.

13 Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia:an international study of 891 patients[J]. Blood, 2011, 117:5857-5859.

14 Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis:incidence and risk factors[J]. Blood, 2010, 115:778-782.

15 Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia:interaction with treatment, standard risk factors, and JAK2 mutation status[J]. Blood, 2007, 109:2310-2313.

16 Vannucchi AM. JAK2 mutation and thrombosis in the myeloproliferative neoplasms[J]. Curr Hematol Malig Rep, 2010, 5:22-28.

17 Tefferi A. The granulocyte connection in MPD-associated thrombosis[J]. Blood, 2007, 109:2270-2271.

18 Zerjavic K, Zagradisnik B, Stangler S, et al. Is the JAK2V617F mutation a hallmark for different forms of thrombosis?[J]. Acta Haematol, 2010, 124:49-56.

19 McCarthy N, McCarron SL, Langabeer SE, et al. Prevalence of the JAK2V617F and MPL mutations in stroke, abdominal and peripheral venous thrombosis[J]. Acta Haematol, 2010, 124:160-161.

20 Ziakas PD. Effect of JAK2V617F on thrombotic risk in patients with essential thrombocythemia:measuring the uncertain[J]. Haematologica, 2008, 93:1412-1414.

21 Kurosawa H, Okuya M, Matsushita T, et al. JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis[J]. J Pediatr Hematol Oncol, 2009, 31:678-680.

22 Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:a critical reappraisal[J]. Leukemia, 2008, 22:1299-1307.

23 De Stefano V, Za T, Rossi E, et al. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2V617F mutation[J]. Ann Hematol, 2010, 89:141-146.

24 Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden[J]. Leukemia, 2007, 21:1952-1959.

25 Xavier SG, Gadelha T, Rezende SM, et al. JAK2V617F mutation in patients with thrombosis:to screen or not to screen?[J]. Int J Lab Hem, 2011, 33:117-124.

26 Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia:relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules[J]. Exp Hematol, 2007, 35:702-711.

27 Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia[J]. Blood, 2010, 116:1205-1210.

28 Barbui T. How to manage thrombosis in myeloproliferative neoplasms[J]. Curr Opin Oncol, 2011, 23:654-658.

29 Bogousslavsky J, Van Melle G, Regli F, et al. The Lausanne Stroke Registry:Analysis of 1,000 consecutive patients with first stroke[J]. Stroke, 1988, 19:1083-1092.

30 Adams HP, Butler MJ, Biller J, et al. Nonhemorrhagic cerebral infarction in young adults[J]. Arch Neurol, 1986, 43:793-796.

[1]	ZHANG Liyuan, LIU Tao, JIANG Yong, LI Zixiao, WANG Yongjun, YANG Xiaomeng. A Machine Learning Model Based on Brain Imaging and Clinical Features for Predicting Atrial Fibrillation Detected after Stroke [J]. Chinese Journal of Stroke, 2025, 20(4): 392-400.
[2]	PU Shanyu, PAN Yuesong, WANG Yongjun. Unsupervised Learning-Based Identification of Responders to Indobufen Treatment in Acute Moderate-to-Severe Ischemic Stroke [J]. Chinese Journal of Stroke, 2025, 20(4): 410-417.
[3]	JIANG Lan, FU Xinmin, SUN Mengfei, LI Yiping. Risk Factors Analysis and Prediction Model Development for Poor Prognosis after Endovascular Treatment of Middle Cerebral Artery Occlusive Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2025, 20(4): 418-427.
[4]	NI Dianli, CHEN Xiaobing, ZHANG Guanghui, PENG Qingrong. Construction and Evaluation of Pre-Hospital Delay Risk Prediction Model for Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2025, 20(4): 428-434.
[5]	ZHANG Xinyue, CHANG Hong, ZHAO Jie, LI Peipei, LIU Mengrao, LI Suai. Correlation between Cognitive Load and Physiological Indicators in Motor Imagery Training in Patients with Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2025, 20(4): 435-446.
[6]	WANG Yan, HAO Huaiyu, LU Qiang, ZHANG Lei, SHEN Xueyan, WEI Guimei. Effects of the Ratio of Extracellular Water to Total Body Water on Discharge Outcomes in Patients with Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2025, 20(4): 457-461.
[7]	HU Yanqin, ZHAO Taoli, LI Shen, GUO Dongxing, ZHAO Zhigang. Meta-Analysis of the Efficacy and Safety of Intravenous Ginkgo Biloba Leaf Preparation in the Treatment of Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2025, 20(4): 462-469.
[8]	ZHAO Qiankun, LI Xiandong, XU Tiance, CHEN Huisheng. Research Progress on the Mechanism of Acupuncture in Treating Ischemic Stroke Based on the Gut-Brain Axis [J]. Chinese Journal of Stroke, 2025, 20(4): 486-492.
[9]	CHI Qi, ZHAO Ying, HAN Dongqian, ZHANG Siqi, DU Peijie, DONG Wanyue, XU Anding, YANG Zhenguo, MENG Heng. Research Progress in Assessing the Onset Time of Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2025, 20(4): 493-499.
[10]	ZHAO Kaijie, SUN Xiuting, YUAN Man, HU Wanzhen, ZHANG Xiaoyan. Advances in Cerebral Collateral Circulation Assessment Methods [J]. Chinese Journal of Stroke, 2025, 20(4): 500-510.
[11]	GUO Yuanli, GAO Renke, YANG Caixia, FAN Wenfeng, GUO Li’na, DONG Xiaofang, LYU Peihua, GAO Huanhuan, MA Keke. Development and Reliability and Validity Testing of the Intravenous Thrombolysis Intention Scale for Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2025, 20(4): 511-518.
[12]	ZHONG Liling, XU Dihao, SONG Jianxun, LIN Guohui, FU Nianxia. HR-VWI Analysis of Vertebrobasilar Artery Geometric Shapes and Basilar Artery Plaques in Patients with Symptomatic Acute Ischemic Stroke in the Posterior Circulation [J]. Chinese Journal of Stroke, 2025, 20(3): 333-340.
[13]	CHEN Songwei, CHEN Hongxiu, DUAN Jiangang, CUI Liuping, LIU Ran, XING Yingqi. Impaired Dynamic Cerebral Autoregulation in Patients with Cerebral Venous Sinus Thrombosis: Evaluation Using Transcranial Doppler and Silent Reading Stimulation [J]. Chinese Journal of Stroke, 2025, 20(3): 357-364.
[14]	XU Bingdong, LIN Yingze, WANG Shuhong, YANG Danping, XU Anding, ZHANG Yusheng. Focusing on the Identification and Management of Patients with Cancer-Associated Ischemic Stroke [J]. Chinese Journal of Stroke, 2025, 20(2): 131-136.
[15]	WANG Shuhong, XU Bingdong, LIN Yingze, YANG Danping, ZHANG Yusheng. Research Progress on the Pathogenesis of Cancer-Associated Ischemic Stroke [J]. Chinese Journal of Stroke, 2025, 20(2): 138-143.